Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This will be a double-blind, randomized, placebo-controlled, single dose study of (+)-
epicatechin with one 30mg dose/day for a total of 7 days
Phase:
Phase 1
Details
Lead Sponsor:
Veterans Medical Research Foundation
Collaborators:
National Center for Complementary and Integrative Health (NCCIH) National Institutes of Health (NIH) San Diego Veterans Healthcare System University of California, San Diego